Background: Atrial Fibrillation (AF), the most commonly diagnosed arrhythmia, results in significant morbidity, mortality and cost to health care system. Additionally, considerable impairment in the quality of life (QoL) is noticed in majority of AF patients. Therapeutic strategies for AF are continuously evolving; catheter ablation (CA) has been shown to be a highly effective treatment option for drug-refractory cases. Absence of recurrence is considered as a successful procedure outcome in CA.

